市場調査レポート

世界の疼痛管理療法市場:産業分析・規模・シェア・成長率・動向・予測

Pain Management Therapeutics Market (Anticonvulsants, Antidepressants, Anesthetics, NSAIDs, Opioids, Other Non-Narcotic Analgesics and Anti-Migraine Agents) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

発行 Transparency Market Research 商品コード 277689
出版日 ページ情報 英文 155 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
世界の疼痛管理療法市場:産業分析・規模・シェア・成長率・動向・予測 Pain Management Therapeutics Market (Anticonvulsants, Antidepressants, Anesthetics, NSAIDs, Opioids, Other Non-Narcotic Analgesics and Anti-Migraine Agents) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
出版日: 2013年07月31日 ページ情報: 英文 155 Pages
概要

世界の疼痛管理療法市場は、2012年から2018年の予測期間にかけて、主要なベストセラー薬の特許期限切れにより、収益が減少すると予測されています。

当レポートでは、世界の疼痛管理療法市場について調査し、セグメント(医薬品の治療クラス、適応症、地域)および2次セグメント(抗けいれん薬、抗うつ薬、麻酔薬、NSAIDs、オピオイド、抗片頭痛薬、その他の非麻薬性鎮痛薬)別の市場分析、主要企業の市場シェアを含む競合分析などをまとめ、概略以下の構成でお届けします。

第1章 序文

  • 調査概説
  • 市場区分
  • 調査手法

第2章 エグゼクティブサマリー

第3章 市場概要

  • 疼痛管理のイントロダクション:治療のタイプ
  • WHO(世界保健機関)によるがん性疼痛の「段階」
  • 市場動向・将来の展望
  • 市場成長促進因子
  • 市場成長阻害因子
  • 市場機会
  • ポーターのファイブフォース分析
  • 市場魅力分析:世界の疼痛管理療法市場‐地域別

第4章 北米の同軸ケーブル市場 - 用途別

  • 抗けいれん薬
  • 抗うつ薬
  • 麻酔薬
  • NSAIDs(非ステロイド性抗炎症薬)
  • オピオイド
  • 抗片頭痛薬
  • その他の非麻薬性鎮痛薬(アセトアミノフェン)

第5章 世界の疼痛管理療法市場:適応症別

  • 神経因性疼痛
  • 線維筋痛
  • 関節痛
  • 慢性腰痛
  • 偏頭痛
  • 術後疼痛
  • がん性疼痛

第6章 世界の疼痛管理療法市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 競合情勢

  • 市場シェア分析
  • パイプラインのスナップショット

第8章 提言

  • 新しい複合製剤の開発
  • アンメットニーズへの対応:薬物乱用・副作用
  • ジェネリック医薬品メーカー:インド・中国・ロシアなどの新興市場における投資
  • 市場参入または市場プレゼンス強化のためのM&A

第9章 企業プロファイル

図表リスト

目次

The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics.

The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations.

Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market.

The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Some of the major players profiled in this report include Abbott Laboratories, Inc., AstraZeneca PLC, Eli Lilly & Co., Endo Health Solutions, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Purdue Pharma LP.

The global pain management market is segmented into the following categories:

Pain Management Therapeutics Market, by Therapeutic Class

  • Anticonvulsants
  • Antidepressants
  • Anesthetics
  • NSAIDs
  • Opioids
  • Other Non-Narcotic Analgesics (Acetaminophen)
  • Anti-Migraine Agents

Pain Management Therapeutics Market, by Indication

  • Neuropathic Pain
  • Fibromyalgia
  • Arthritic Pain, by Type
    • Osteoarthritis
    • Rheumatoid Arthritis
  • Chronic Back Pain
  • Migraine
  • Post-operative Pain
  • Cancer Pain

Pain Management Therapeutics Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 - Preface

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

Chapter 2 - Executive Summary

Chapter 3 - Market Overview

  • 3.1. Introduction to Pain Management - Types of Treatments
  • 3.2. World Health Organization's “Pain Ladder” for cancer
  • 3.3. Market Trends and Future Outlook
    • 3.3.1. Impact of generics
    • 3.3.2. Key patent expirations
  • 3.4. Market Drivers
    • 3.4.1. Global increasing incidence of chronic pain disorders
    • 3.4.2. Favorable regulatory scenario and healthcare reforms
    • 3.4.3. Easy and effective medications
    • 3.4.4. Impact analysis of market drivers
  • 3.5. Market Restraints
    • 3.5.1. Prescription drug abuse
    • 3.5.2. Pain advocacy groups losing power, influence and funding
    • 3.5.3. Adulteration and fake drugs thrive in developing regions
    • 3.5.4. Long term pain relief from surgical procedures, alternative therapies and medical devices
    • 3.5.5. Impact analysis of market restraints
  • 3.6. Market Opportunities
    • 3.6.1. Novel molecule combinations and drug delivery techniques are expected to become a rising opportunity in forecast period
    • 3.6.2. Generics expected to be a rising opportunity lgobally
  • 3.7. Porter's Five Forces Analysis
    • 3.7.1. Bargaining power of buyers
    • 3.7.2. Bargaining power of suppliers
    • 3.7.3. Threat of substitutes
    • 3.7.4. Threat of new entrants
    • 3.7.5. Competitive rivalry
  • 3.8. Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)

Chapter 4 - Global Pain Management Therapeutics Market, by Therapeutic Class

  • 4.1. Anticonvulsants
    • 4.1.1. Current and future market scenario
  • 4.2. Antidepressants
    • 4.2.1. Current market scenario and patent expiry effect
    • 4.2.2. Future market scenario
  • 4.3. Anesthetics
    • 4.3.1. Current market scenario and patent expiry effect
    • 4.3.2. Pipeline drugs and their effect
    • 4.3.3. General Anesthetics
    • 4.3.4. Local Anesthetics
  • 4.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 4.4.1. Current market scenario and patent expiry effect
  • 4.5. Opioids
    • 4.5.1. Current market scenario and patent expiry effect
    • 4.5.2. Pipeline drugs and their effect on the market
      • 4.5.2.1. MoxDuo IR
      • 4.5.2.2. Remoxy
  • 4.6. Anti-Migraine Agents
    • 4.6.1. Pipeline drugs and additional approvals
  • 4.7. Other Non-Narcotic Analgesics (Acetaminophen)

Chapter 5 - Global Pain Management Therapeutics Market, by Indication

  • 5.1. Neuropathic Pain
  • 5.2. Fibromyalgia
  • 5.3. Arthritic Pain
    • 5.3.1. Osteoarthritis (OA)
    • 5.3.2. Rheumatoid Arthritis (RA)
  • 5.4. Chronic Back Pain
  • 5.5. Migraine
  • 5.6. Post-operative pain
  • 5.7. Cancer Pain

Chapter 6 - Global Pain Management Therapeutics Market, by Geography

  • 6.1. Overview
    • 6.1.1. Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 - 2018 (USD Million)
    • 6.1.2. Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)
  • 6.2. North America
    • 6.2.1. North America Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
  • 6.4. Asia-Pacific
    • 6.4.1. Asia-Pacific Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
  • 6.5. Rest of the World (RoW)
    • 6.5.1. RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

Chapter 7 - Competitive Landscape

  • 7.1. Market Share Analysis: Global Pain Management Therapeutics Market (2011)
    • 7.1.1. Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)
    • 7.1.2. Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)
  • 7.2. Pipeline Snapshot: Pain Management Therapeutics
    • 7.2.1. MoxDuo (morphine and oxycodone)
    • 7.2.2. Remoxy (oxycodone)
    • 7.2.3. Posidur (SABER-bupivacaine)
    • 7.2.4. Zecuity (transdermal sumatriptan)

Chapter 8 - Recommendations

  • 8.1. Development of novel combination formulations
  • 8.2. Addressing unmet needs: drug abuse and side-effects
  • 8.3. Generics manufacturers: Investment in emerging markets such as India, China and Russia
  • 8.4. Mergers and acquisitions to enter or strengthen market presence

Chapter 9 - Company Profiles

  • 9.1. Abbott Laboratories
    • 9.1.1. Company Overview
    • 9.1.2. Financial Overview
    • 9.1.3. Product Portfolio
    • 9.1.4. Business Strategies
    • 9.1.5. Recent Developments
  • 9.2. Allergan, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Overview
    • 9.2.3. Product Portfolio
    • 9.2.4. Business Strategies
    • 9.2.5. Recent Developments
  • 9.3. Covidien plc
    • 9.3.1. Company Overview
    • 9.3.2. Financial Overview
    • 9.3.3. Product Portfolio
    • 9.3.4. Business Strategies
    • 9.3.5. Recent Developments
  • 9.4. Durect Corporation
    • 9.4.1. Company Overview
    • 9.4.2. Financial Overview
    • 9.4.3. Pipeline Products
    • 9.4.4. Business Strategies
    • 9.4.5. Recent Developments
  • 9.5. Eli Lilly and Company
    • 9.5.1. Business Overview
    • 9.5.2. Financial Overview
    • 9.5.3. Product Portfolio
    • 9.5.4. Business Strategies
    • 9.5.5. Recent Developments
  • 9.6. Endo Health Solutions, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Overview
    • 9.6.3. Product Portfolio
    • 9.6.4. Business Strategies
    • 9.6.5. Recent Developments
  • 9.7. Forest Laboratories, Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Overview
    • 9.7.3. Product Portfolio
    • 9.7.4. Business Strategies
    • 9.7.5. Recent Developments
  • 9.8. GlaxoSmithKline plc
    • 9.8.1. Company Overview
    • 9.8.2. Financial Overview
    • 9.8.3. Product Portfolio
    • 9.8.4. Business Strategies
    • 9.8.5. Recent Developments
  • 9.9. Hospira, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Overview
    • 9.9.3. Product Portfolio
    • 9.9.4. Business Strategies
    • 9.9.5. Recent Developments
  • 9.10. Johnson & Johnson
    • 9.10.1. Company Overview
    • 9.10.2. Financial Overview
    • 9.10.3. Product Portfolio
    • 9.10.4. Business Strategies
    • 9.10.5. Recent Developments
  • 9.11. Merck & Co., Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Overview
    • 9.11.3. Product Portfolio
    • 9.11.4. Business Strategies
    • 9.11.5. Recent Developments
  • 9.12. Mundipharma International Ltd.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Overview
    • 9.12.3. Product Portfolio
    • 9.12.4. Business Strategies
    • 9.12.5. Recent Developments
  • 9.13. Novartis International AG
    • 9.13.1. Company Overview
    • 9.13.2. Financial Overview
    • 9.13.3. Product Portfolio
    • 9.13.4. Business Strategies
    • 9.13.5. Recent Developments
  • 9.14. NuPathe, Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Financial Overview
    • 9.14.3. Product Portfolio
    • 9.14.4. Business Strategies
    • 9.14.5. Recent Developments
  • 9.15. Pain Therapeutics, Inc.
    • 9.15.1. Company Overview
    • 9.15.2. Financial Overview
    • 9.15.3. Product Portfolio
    • 9.15.4. Business Strategies
    • 9.15.5. Recent Developments
  • 9.16. Pfizer, Inc.
    • 9.16.1. Company Overview
    • 9.16.2. Financial Overview
    • 9.16.3. Product Portfolio
    • 9.16.4. Business Strategies
    • 9.16.5. Recent Developments
  • 9.17. Purdue Pharma L.P.
    • 9.17.1. Company Overview
    • 9.17.2. Financial Overview
    • 9.17.3. Product Portfolio
    • 9.17.4. Business Strategies
    • 9.17.5. Recent Developments
  • 9.18. QRx Pharma Ltd.
    • 9.18.1. Company Overview
    • 9.18.2. Financial Overview
    • 9.18.3. Product Portfolio
    • 9.18.4. Business Strategies
    • 9.18.5. Recent Developments
  • 9.19. Sanofi
    • 9.19.1. Company Overview
    • 9.19.2. Financial Overview
    • 9.19.3. Product Portfolio
    • 9.19.4. Business Strategies
    • 9.19.5. Recent Developments
  • 9.20. Teva Pharmaceutical Industries Limited
    • 9.20.1. Company Overview
    • 9.20.2. Financial Overview
    • 9.20.3. Product Portfolio
    • 9.20.4. Business Strategies
    • 9.20.5. Recent Developments
  • 9.21. UCB (Union Chemnique Belge) S.A.
    • 9.21.1. Company Overview
    • 9.21.2. Financial Overview
    • 9.21.3. Product Portfolio
    • 9.21.4. Business Strategies
    • 9.21.5. Recent Developments

List of Figures

  • FIG. 1: Pain Management Therapeutics Market Segmentation
  • FIG. 2: Global Pain Management Therapeutics Market, by Therapeutic Class, 2011 (USD Million)
  • FIG. 3: Global Pain Management Therapeutics Market, by Indication, 2011 (USD Million)
  • FIG. 4: Porter's Five Forces Analysis: Global Pain Management Therapeutics Market
  • FIG. 5: Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)
  • FIG. 6: Global Anticonvulsants Market for Pain Management, 2010 - 2018 (USD Million)
  • FIG. 7: Global Antidepressants Market for Pain Management, 2010 - 2018 (USD Million)
  • FIG. 8: Global Antidepressants Market for Pain Management, 2010 - 2015 (USD Million)
  • FIG. 9: Global Antidepressants Market for Pain Management, 2015 - 2018 (USD Million)
  • FIG. 10: Global Anesthetics Market, 2010 - 2018 (USD Million)
  • FIG. 11: Global Anesthetics Market, 2010 - 2015 (USD Million)
  • FIG. 12: Global Anesthetics Market, 2015 - 2018 (USD Million)
  • FIG. 13: Global General Anesthetics Market, 2010 - 2018 (USD Million)
  • FIG. 14: Global Local Anesthetics Market, 2010 - 2018 (USD Million)
  • FIG. 15: Global Non-Steroidal Anti-Inflammatory Drugs Market, 2010 - 2018 (USD Million)
  • FIG. 16: Global Opioids Market, 2010 - 2018 (USD Million)
  • FIG. 17: Global Opioids Market, 2010 - 2015 (USD Million)
  • FIG. 18: Global Opioids Market, 2015 - 2018 (USD Million)
  • FIG. 19: Global Anti-Migraine Agents Market, 2010 - 2018 (USD Million)
  • FIG. 20: Global Anti-Migraine Agents Market, 2015 - 2018 (USD Million)
  • FIG. 21: Global Other Non-Narcotic Analgesics Market, 2010 - 2018 (USD Million)
  • FIG. 22: Global Neuropathic Pain Market, 2010 - 2018 (USD Million)
  • FIG. 23: Global Fibromyalgia Market, 2010 - 2018 (USD Million)
  • FIG. 24: Global Arthritic Pain Market, 2010 - 2018 (USD Million)
  • FIG. 25: Global Chronic Back Pain Market, 2010 - 2018 (USD Million)
  • FIG. 26: Global Migraine Market, 2010 - 2018 (USD Million)
  • FIG. 27: Global Post-operative Pain Market, 2010 - 2018 (USD Million)
  • FIG. 28: Global Cancer Pain Market, 2010 - 2018 (USD Million)
  • FIG. 29: Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)
  • FIG. 30: North America Pain Management Therapeutics Market, 2010 - 2018 (USD Million)
  • FIG. 31: Europe Pain Management Market, 2010 - 2018 (USD Million)
  • FIG. 32: Asia-Pacific Pain Management Therapeutics Market, 2010 - 2018 (USD Million)
  • FIG. 33: RoW Pain Management Therapeutics Market, 2010 - 2018 (USD Million)
  • FIG. 34: Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)
  • FIG. 35: Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)
  • FIG. 36: Posidur Vs Others: A Comparison of Pain Relief Duration
  • FIG. 37: Annual Revenues: Abbott Laboratories, 2010 - 2012 (USD million)
  • FIG. 38: Annual Revenues: Allergan, Inc., 2010 - 2012 (USD million)
  • FIG. 39: Annual Revenues: Covidien plc, 2010 - 2012 (USD million)
  • FIG. 40: Annual Revenues: Durect Corporation., 2010 -2012 (USD million)
  • FIG. 41: Annual Revenues: Eli Lilly and Company, 2010 - 2012 (USD million)
  • FIG. 42: Annual Revenues: Endo Health Solutions, Inc., 2010 - 2012 (USD million)
  • FIG. 43: Annual Revenues: Forest Laboratories, Inc., 2010 - 2012 (USD million)
  • FIG. 44: Annual Revenues: GlaxoSmithKline plc, 2010 - 2012 (USD million)
  • FIG. 45: Annual Revenues: Hospira, Inc., 2010 - 2012 (USD million)
  • FIG. 46: Annual Revenues: Johnson & Johnson, 2010 - 2012 (USD million)
  • FIG. 47: Annual Sales: Merck & Co., 2010 - 2012 (USD million)
  • FIG. 48: Annual Revenues: Novartis international AG , 2010 - 2012 (USD million)
  • FIG. 49: Annual Revenues: Pain Therapeutics, Inc., 2010 - 2012 (USD million)
  • FIG. 50: Annual Revenues: Pfizer, Inc., 2010 - 2012 (USD million)
  • FIG. 51: Annual Revenues: QRx Pharma Ltd., 2010 - 2012 (USD million)
  • FIG. 52: Annual Sales: Sanofi, 2010 - 2012 (USD million)
  • FIG. 53: Annual Revenues: Teva Pharmaceutical Industries Limited, 2010 - 2012 (USD million)
  • FIG. 54: Annual Revenues: UCB, S.A., 2010 - 2012 (USD million)

List of Tables

  • TABLE 1: Market Snapshot: Global Pain Management Therapeutics Market
  • TABLE 2: Impact Analysis of Market Drivers
  • TABLE 3: Impact Analysis of Market Restraints
  • TABLE 4: Global Anesthetics Market, by Segments, 2010 - 2018 (USD Million)
  • TABLE 5: Licensed Pharmaceuticals for Neuropathic Pain Management
  • TABLE 6: Key Licensed Pharmaceuticals for Arthritic Pain Management
  • TABLE 7: Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 - 2018 (USD Million)
  • TABLE 8: North America Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
  • TABLE 9: Europe Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
  • TABLE 10: Asia-Pacific Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
  • TABLE 11: RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
Back to Top